Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease
| Autor: | Jolanta Malyszko, Jacek S. Malyszko, Joanna Matuszkiewicz-Rowińska |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Anemia Iron medicine.medical_treatment Clinical Biochemistry Inflammation urologic and male genital diseases Gastroenterology Pathogenesis 03 medical and health sciences 0302 clinical medicine Drug Development Hepcidins Hepcidin hemic and lymphatic diseases Internal medicine Drug Discovery medicine Animals Humans Erythropoiesis Molecular Targeted Therapy Renal Insufficiency Chronic Dialysis Pharmacology biology business.industry Molecular control medicine.disease female genital diseases and pregnancy complications 030104 developmental biology Erythropoietin 030220 oncology & carcinogenesis biology.protein Molecular Medicine medicine.symptom business medicine.drug Kidney disease |
| Zdroj: | Expert Opinion on Therapeutic Targets. 23:407-421 |
| ISSN: | 1744-7631 1472-8222 |
| Popis: | Anemia is a common manifestation of chronic kidney disease (CKD). The pathogenesis of CKD-associated anemia is multifactorial. Our understanding of the molecular control of iron metabolism has improved dramatically because of the discovery of hepcidin and attempts to introduce new drugs to stimulate erythropoiesis or affect the hepcidin-ferroportin pathway have recently emerged. Areas covered: We examine the possible role of hepcidin in iron metabolism and regulation and the potential therapeutic options involving hepcidin and hepcidin-ferroportin axis in renal anemia treatment. We focus on therapeutic targeting of hepcidin, the hepcidin-ferroportin axis and key molecules such as anti-hepcidin antibodies, spigelmers, and anticalins. We also discuss compounds affecting the bone morphogenetic protein receptor [BMP/BMPR] complex and molecules that influence hepcidin, such as hypoxia-inducible factor 1 stabilizers. Expert opinion: Hepcidin is a key regulator of iron availability and is a potential future therapeutic target for managing anemia that is associated with CKD. There are potential risks and benefits associated with novel sophisticated therapies and there are several novel options on the horizon; however, clinical data are currently limited and need development. Inhibition of hepcidin via various pathways might be a viable adjunctive therapeutic option in other clinical situations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|